UNSPSC 51101674: Nitarsone

This classification denotes an antiprotozoal agent with the molecular formula C6H6AsNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JP2EN8WORU, chemically known as benzenearsonic acid, p-nitro- but generally known as nitarsone, which bears US NIH Compound Identifier 66826. European Medicines Agency schedules Nitarsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09310MIG.

UNSPSC 51101674 Nitarsone, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally covers nitarsone, a specific pharmaceutical active ingredient historically used in veterinary applications, but recent state and local solicitations tagged to this code involve entirely different product categories—naloxone (an opioid antagonist), safe drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. State and local buyers posting under this code appear to be health departments, fire departments, HHS agencies, and cooperative purchasing alliances across multiple states, but the tagged opportunities bear no relationship to nitarsone's actual scope.

The recent opportunities across Florida, Texas, Minnesota, and Oregon reflect procurement for emergency medical supplies, community health initiatives, and pharmaceutical distribution partnerships, none of which align with nitarsone as a discrete product category. Seminole County, Florida issued IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term. The Texas HHS Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription fulfillment capabilities. The City of Tampa's Purchasing Department sought medical and first aid supplies via ITB 26P00145 in March 2026 for the Fire Department Rescue Division, with an estimated contract value of $700,000 and an SLBE set-aside. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and an effective date of July 1, 2026. The code does not reflect meaningful procurement activity for nitarsone as a distinct product line in state and local markets.